Stocks to sell

Short squeeze stocks are no new phenomenon. But so far this year, thanks to the potent combination of meme stocks and Reddit trading? It’s been an easy way for retail investors to make fast trading profits. Between AMC Entertainment (NYSE:AMC), Clover Health (NASDAQ:CLOV), GameStop (NYSE:GME) and many others, quick to the punch Main Street traders

Investors were already selling Skillz (NYSE:SKLZ) stock before the company posted quarterly earnings results on Aug. 3. Source: Rawpixel.com/Shutterstock.com After the report, SKLZ stock slumped further. Clearly there is something the market does not like about this electronic gaming and multimedia firm. At these levels, investors might think the stock has less risk and more

My feelings about DiDi Global Inc. (NYSE:DIDI) can probably be summed up by saying it’s riskier than a new driver tackling “Death Road.” Otherwise known as the North Yungas Road in Bolivia, it’s one of the most dangerous roads on earth. As Lookers states in an article, “It has been estimated that around 200-300 people

Okay, I’ll admit it. I’ve flip-flopped on SOS Limited (NYSE:SOS). In March, I recommended sitting on the sidelines. Then in May, I advised gradually accumulating shares of SOS stock. Source: Mark Agnor / Shutterstock.com Between the flipping and the flopping, I noticed some strange things about SOS Limited. As we’ll see, my colleagues at InvestorPlace also detected

“The future of sports is electronic. The future of sports is mobile. The future of sports is now.” This is what Skillz Inc. (NYSE:SKLZ) says in a video about how it works. But if this is the future of sports, then why did SKLZ stock fall over 45% year to date to Monday’s close of

Context Logic (NASDAQ:WISH) stock has had a rough few weeks. Source: sdx15 / Shutterstock.com The company posted dismal second-quarter results and expected the slowdown to continue in the third quarter. Consequently, WISH stock is down more than 30% this month. Long-term growth drivers are in place, but its troubling fundamentals and business risks have me

The U.S. public and the market are belatedly realizing that the Delta variant of the coronavirus is not very dangerous, especially to those who are vaccinated and won’t stay in the U.S. for many months. Consequently, now is not a good time to buy highly valued stocks that thrive when consumers stay at home more.

This is certainly an odd economy. On one hand, the delta variant is a dark shadow over how long economic expansion lasts. On the other, the economy is booming and oil stocks have gone from zeros to heroes in the past year. The S&P Global Oil Index, which measures the performance of 120 of the

DiDi Global (NYSE:DIDI) could easily fall quite significantly to the value of just its non-China operations, plus its net cash (as long as that cash is not in China). This is because Chinese regulators have placed the company under dire restrictions. If that happens, I estimate that DIDI stock would be worth no more than

Right now everyone loves Square (NASDAQ:SQ) stock. Source: Jonathan Weiss / Shutterstock.com The company only came public in 2015, at a market cap of $2.9 billion. Today that number is right around $124 billion. At its current value Square is the third most valuable payment outfit, behind only MasterCard (NYSE:MA) and Visa (NYSE:V). But it

How far can a small medical devices company take a celebrity endorsement? The shares of veterinary diagnostics company Zomedica (NYSEAMERICAN:ZOM) surged after an endorsement from Tiger King celebrity Carole Baskin. In response, meme traders bid ZOM stock up sharply. Since the short interest in ZOM stock is high, the news created a dramatic short squeeze. Source:

Clover Health (NASDAQ:CLOV) has been one of the year’s biggest disappointments. The so-called King of SPACs (special purpose acquisition companies), Chamath Palihapitiya, took the health insurer public via one of his Social Capital Hedosophia SPACs. CLOV stock shares almost immediately tumbled after short sellers revealed that it had failed to disclose a government investigation into

Outlier Covid-19 vaccine play Ocugen (NASDAQ:OCGN) stock has been on a negative run in the past three months, losing about 17% of its value. Source: Shutterstock The company failed to gain an emergency use authorization (EUA) from the FDA for Covaxin, the Indian variant of the coronavirus vaccine. Moreover, its partner firm Bharat Biotech is

If you think Carnival (NYSE:CCL) and CCL stock is a good bet at almost $24, you might want to think again. Covid-19 is still very much still an “unwanted passenger” on its cruise ships. As a result, a resumption to pre-pandemic cruising — as well as improvements in the CCL stock price — seem like they’re

This is my first time writing about Novavax (NASDAQ:NVAX) and the more I learn about the company, I can’t help but think about Inception, the Leonardo DiCaprio movie about dreams within dreams. A lot of the discussion around Novavax’s Covid-19 vaccine feels like living in that film’s impossible dream worlds. People buying NVAX stock are believing

Tilray (NASDAQ:TLRY) stock has become one of the biggest cannabis names following the Aphria-Tilray business combination. Source: Jarretera / Shutterstock.com The newly combined company now has a much greater chance at carving out a piece of the U.S. market following the deal.  But the company is also currently making headlines in regard to other deal

GameStop (NYSE:GME) remains one of the year’s most remarkable stock market stories. GME stock enjoyed not one but two historic short squeezes, leading to windfall profits for longs and incredible pain for skeptics such as Melvin Capital. Source: rblfmr / Shutterstock.com However, the fun may be winding down for GameStop. Shares have been sliding for

With poor financial results, declining market share and no access to the U.S. market, Canadian cannabis producer Canopy Growth (NASDAQ:CGC) stock remains difficult to bet on. Source: Shutterstock CGC stock is down 33% so far this year and the slide shows no signs of ending anytime soon. At $17.47, the company’s shares are now at

Cassava Sciences (NASDAQ:SAVA) is a biotech company with an important goal: fighting Alzheimer’s disease. It has several treatments in development, but is SAVA stock worth adding to your portfolio? Source: Shutterstock Obviously, I want this company to succeed; I witnessed a family friend’s battle with Alzheimer’s disease, and I would love for Cassava to succeed

AT&T (NYSE:T) announced on May 17 that it would spin-off its WarnerMedia subsidiary and merge it with Discovery Communications (NASDAQ:DISCA, NASDAQ:DISCB, NASDAQ:DISCK) to create another massive media conglomerate. T stock has lost 13% of its value in the three months since.  Source: Shutterstock In 2021, AT&T’s stock has traded below $30 for all but a